Brief: Bellus Health says Kiacta did not meet primary efficacy endpoint in phase 3 study

BELLUS Health

20/06/2016 13:06

June 20 (Reuters) - Bellus Health Inc  
    * Announces top-line phase 3 results of kiacta for treatment 
of aa amyloidosis 
    * In study, Kiacta did not meet primary efficacy endpoint in 
slowing renal function decline 
    * Kiacta was shown to be safe and well tolerated over 
treatment periods of greater than 4 years 
    * Further analysis of data is ongoing. 
 
Source text for Eikon:  ID:nCNW5MnhYa  
Further company coverage:  BLU.TO  
 
 (Bengaluru Newsroom: +1 646 223 8780)